featured
Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for Early-Stage NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2024 Sep 28;404(10459)11240-1252, JD Spicer, MC Garassino, H Wakelee, M Liberman, T Kato, M Tsuboi, SH Lee, KN Chen, C Dooms, M Majem, E Eigendorff, GL Martinengo, O Bylicki, D Rodríguez-Abreu, JE Chaft, S Novello, J Yang, A Arunachalam, SM Keller, A Samkari, S GaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.